| Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy A Rayati Damavandi, R Dowran, S Al Sharif, F Kashanchi, R Jafari Medical Microbiology and Immunology 211 (2), 79-103, 2022 | 19 | 2022 |
| A review of monkeypox ocular manifestations and complications: insights for the 2022 outbreak A Rayati Damavandi, F Semnani, K Hassanpour Ophthalmology and Therapy 12 (1), 55-69, 2023 | 12 | 2023 |
| Preparedness for future pandemics: lessons learned from the COVID-19 pandemic in Iran A Takian, SS Aarabi, F Semnani, A Rayati Damavandi International journal of public health 67, 1605094, 2022 | 7 | 2022 |
| Reinfection and reactivation of SARS-CoV-2 R Dowran, AR Damavandi, TM Azad Future virology 17, 835-844, 2022 | 6 | 2022 |
| The current state of knowledge on how to improve skin flap survival: A review A Afrooghe, AR Damavandi, E Ahmadi, RM Jafari, AR Dehpour Journal of Plastic, Reconstructive & Aesthetic Surgery, 2023 | 5 | 2023 |
| Reverse zoonosis and monkeypox: Time for a more advanced global surveillance system for emerging pathogens A Afrooghe, AR Damavandi, E Ahmadi New Microbes and New Infections 48, 2022 | 5 | 2022 |
| Advances in nanotechnology versus stem cell therapy for the theranostics of multiple sclerosis disease AR Damavandi, O Mirmosayyeb, N Ebrahimi, H Zalpoor, P Khalilian, ... Applied Nanoscience 13 (6), 4043-4073, 2023 | 4 | 2023 |
| The Association of Programmed Death 1 Gene Polymorphisms of PD1. 3 G/A and PD1. 5 C/T with Risk of COVID-19 in an Iranian Population: A Case–Control Study A Rayati Damavandi, P Zolfaghari Baghbadorani, B Kardideh, ... Viral immunology 35 (7), 483-490, 2022 | 4 | 2022 |
| Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy A Aghamajidi, P Farhangnia, S Pashangzadeh, AR Damavandi, R Jafari Cancer Cell International 22 (1), 327, 2022 | 3 | 2022 |
| Current advances in stem cell therapy in the treatment of multiple sclerosis P Zolfaghari Baghbadorani, A Rayati Damavandi, S Moradi, M Ahmadi, ... Reviews in the Neurosciences 34 (6), 613-633, 2023 | 2 | 2023 |
| Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020 K Pesudovs, VC Lansingh, JH Kempen, I Tapply, AG Fernandes, ... Eye, 1-15, 2024 | 1 | 2024 |
| Genetic predisposition to ocular surface disorders and opportunities for gene-based therapies D Roshandel, F Semnani, AR Damavandi, A Masoudi, A Baradaran-Rafii, ... The Ocular Surface, 2023 | 1 | 2023 |
| Exosome-carried microRNAs as medicine in lymphoma and related cancers FNA Jahromi, R Dowran, AR Damavandi, R Jafari | 1 | 2023 |
| Monkeypox exposure in patients living with HIV (PLWH): Epidemiological and clinical significance and a summary of response recommendations F Semnani, AR Damavandi, SS Aarabi New Microbes and New Infections 49, 2022 | | 2022 |
| Response to Sriwijitalai and Wiwanitkit re:“The Association of Programmed Death 1 Gene Polymorphisms of PD1. 3 G/A and PD1. 5 C/T with Risk of COVID-19 in an Iranian Population … A Rayati Damavandi, F Fathi, N Eskandari Viral Immunology 35 (7), 515-515, 2022 | | 2022 |
Farbod SemnaniMD | MPH candidate at Tehran University of Medical SciencesVerified email at student.tums.ac.ir
